SCHEMBL1017654

SCHEMBL1017654

CC(=O)c1ccc2c(c1)CCN(CC(=O)N1CCN(C(C)C)CC1)C2

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACACB O00763 4/20 0.45
HRH3 Q9Y5N1 7/20 0.44
ALDH1A1 P00352 2/20 0.44
PKM P14618 2/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KCNH2 Q12809 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
ITGB3 P05106 1/20 0.41
ITGA2B P08514 1/20 0.41
POLB P06746 1/20 0.40
PRMT5 O14744 2/20 0.40
WDR77 Q9BQA1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017851 0.82 MEN1 (0.49) ACACBHRH3ALDH1A1PKMGAA
SCHEMBL1017273 0.81 HRH3 (0.42) ACACBHRH3ALDH1A1PKMGAA
SCHEMBL1018706 0.81 ACACB (0.43) ACACBHRH3ALDH1A1PKMGAA
SCHEMBL1017104 0.81 ALDH1A1 (0.44) ACACBHRH3ALDH1A1PKMGAA
SCHEMBL1017172 0.81 KDM2B (0.45) HRH3ALDH1A1PKMGAAHSD17B10
SCHEMBL1017932 0.81 MAPT (0.44) ACACBHRH3ALDH1A1PKMGAA
SCHEMBL1018762 0.80 RAB9A (0.45) HRH3ALDH1A1PKMGAAHSD17B10
SCHEMBL1014831 0.80 PRMT5 (0.46) ACACBHRH3ALDH1A1PKMGAA
SCHEMBL1604050 0.80 ALDH1A1 (0.50) HRH3ALDH1A1GAAKMT2AKDM4E
SCHEMBL1018776 0.80 HRH3 (0.41) ACACBHRH3ALDH1A1PKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US claimed
US-20140121226-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ACACB 3935/4885HRH3 1/4885ALDH1A1 1229/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ACACB 3935/4885HRH3 1/4885ALDH1A1 1229/4885
US-20140121226-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, CXCR4, CXCR3 ACACB 4112/4885HRH3 80/4885ALDH1A1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.